Belimumab (BENLYSTA®) Pregnancy Registry

Completed

Conditions studied: Systemic Lupus Erythematosus

In brief

This global Belimumab Pregnancy Registry will collect prospective data on pregnancies and pregnancy outcomes on a voluntary basis in women with systemic lupus erythematosus (SLE) who have received commercially supplied belimumab within the 4 months prior to and/or during pregnancy. The registry will also evaluate outcomes of infants born to mothers who were exposed to belimumab within the 4 months prior to and/or during pregnancy. This registry will add to the current clinical experience with belimumab and will complement reproductive data from animal toxicology studies. It will also assist clinicians in weighing the potential risks against the benefits of treatment for individual patients with SLE. GlaxoSmithKline (GSK) will sponsor the Belimumab Pregnancy Registry in countries where it holds Marketing Authorization.

Key facts

Study ID

NCT01532310

Run by

GlaxoSmithKline

People needed

77

Starts

2012-07-16

Expected to finish

2022-11-11

Last updated by the study team

2025-06-10

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Pregnant women containing sufficient evidence to confirm that exposure to commercially supplied belimumab occurred within the 4 months prior to and/or during pregnancy
• Pregnant women with sufficient information to classify the pregnancy as prospective or retrospective (ie,whether the outcome of pregnancy was known at the time of first contact with the registry)
• Pregnant women with full contact information to allow for follow-up (name, address, telephone number/email address) and contact information for applicable HCPs if initial reporter is the pregnant woman
• Consent provided by the pregnant woman for her participation and assent for participation of her infant.

You may not qualify if…

• Reported cases that do not meet the minimum inclusion criteria for registry enrollment will be ineligible for inclusion in the registry

Where it is running

• GSK Investigational Site — Wilmington, North Carolina, United States
• GSK Investigational Site — Wilmington, North Carolina, United States
• GSK Investigational Site — Innsbruck, Austria
• GSK Investigational Site — Liège, Belgium
• GSK Investigational Site — Québec, Quebec, Canada
• GSK Investigational Site — Paris, France
• GSK Investigational Site — Düsseldorf, Germany
• GSK Investigational Site — Tel Litwinsky, Israel
• GSK Investigational Site — Pisa, Italy
• GSK Investigational Site — Almada, Portugal
• GSK Investigational Site — Bilbao, Spain
• GSK Investigational Site — Stockholm, Sweden
• GSK Investigational Site — Bern, Switzerland
• GSK Investigational Site — Sankt Gallen, Switzerland
• GSK Investigational Site — Zurich, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.